1-8 of 8
Manish Gupta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Continuous or Fixed-Duration Treatment for CD3xCD20 Bispecifics: A Modeling and Simulation Study Using Epcoritamab Monotherapy

Xiaozhi Liao, Tommy Li, Steven Xu, Mohamed-Eslam F Mohamed, Mahipal Sinnollareddy, Manish Gupta, Monica Wielgos-Bonvallet, Andrew J. Steele, Mariana Sacchi, Yanguang Cao
Journal: Blood
Blood (2024) 144 (Supplement 1): 1701.
https://doi.org/10.1182/blood-2024-205552
Published: 2024
Journal Articles

Exposure-Response Analyses Supporting Optimal Epcoritamab Full Dose and Dosing Schedule in Relapsed or Refractory Follicular Lymphoma

Mahipal Gurram Sinnollareddy, Leonid Gibiansky, Kinjal Sanghavi, Steven Xu, Mohamed-Eslam F Mohamed, Poliana P. Patah, Elena Favaro, Manish Gupta, Apurvasena Parikh, Tommy Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 1414.
https://doi.org/10.1182/blood-2024-197962
Published: 2024
Journal Articles

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahi Ahmadi, Manish Gupta, Steven Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3135.
https://doi.org/10.1182/blood-2023-181322
Published: 2023
Journal Articles

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, Matthew Putnins, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4481.
https://doi.org/10.1182/blood-2023-179555
Published: 2023
Journal Articles

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Tommy Li, PhD, Ida H Hiemstra, PhD, Christopher Chiu, PhD, Roberto S Oliveri, MD PhD, Dena DeMarco, Theodora W. Salcedo, PhD DABT, Frederikke Lihme Egerod, PhD, Manish Gupta, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-139457
Published: 2020
Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 758.
https://doi.org/10.1182/blood-2019-121460
Published: 2019
Journal Articles

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Jessicca M. Rege, PhD, Blaine W. Robinson, PhD, Manish Gupta, PhD, Jeffrey S. Barrett, PhD, Peter C. Adamson, MD, Kathryn C. Behling, MD, PhD, Andrew D. Bantly, Jonni S. Moore, PhD, Carolyn A. Felix, MD
Journal: Blood
Blood (2005) 106 (11): 3368.
https://doi.org/10.1182/blood.V106.11.3368.3368
Published: 2005
Journal Articles

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Blaine W. Robinson, PhD, Kathyrn C. Behling, MD, PhD, Jeffrey S. Barrett, PhD, Manish Gupta, PhD, Jessicca M. Rege, PhD, Jonni S. Moore, PhD, Andrew D. Bantly, Junhyong Kim, PhD, George Hii, Cheryl L. Willman, MD, Jeffrey Potter, Peter C. Adamson, MD, Carolyn A. Felix, MD
Journal: Blood
Blood (2005) 106 (11): 3360.
https://doi.org/10.1182/blood.V106.11.3360.3360
Published: 2005